Trial Profile
Forteo Voluntary Patient Registry: 3-Year Progress on a Prospective Osteosarcoma Surveillance Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Apr 2021 Status changed from active, no longer recruiting to completed, as per published in the Osteoporosis International
- 01 Apr 2021 Final results of the Forteo Patient Registry assessing long-term safety evidence for teriparatide, published in the Osteoporosis International
- 22 Apr 2014 New trial record